U.S. markets open in 6 hours 55 minutes
  • S&P Futures

    4,130.00
    +2.25 (+0.05%)
     
  • Dow Futures

    33,713.00
    +4.00 (+0.01%)
     
  • Nasdaq Futures

    13,750.75
    +0.50 (+0.00%)
     
  • Russell 2000 Futures

    2,238.30
    +10.00 (+0.45%)
     
  • Crude Oil

    61.73
    +0.30 (+0.49%)
     
  • Gold

    1,784.50
    +2.50 (+0.14%)
     
  • Silver

    26.11
    -0.07 (-0.27%)
     
  • EUR/USD

    1.2028
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    18.71
    +1.21 (+6.91%)
     
  • GBP/USD

    1.3855
    +0.0012 (+0.09%)
     
  • USD/JPY

    107.9430
    -0.0170 (-0.02%)
     
  • BTC-USD

    48,803.42
    -5,408.22 (-9.98%)
     
  • CMC Crypto 200

    1,102.99
    -140.06 (-11.27%)
     
  • FTSE 100

    6,938.24
    +42.95 (+0.62%)
     
  • Nikkei 225

    29,020.63
    -167.54 (-0.57%)
     
  • Oops!
    Something went wrong.
    Please try again later.

Novavax says its vaccine is 89.3% effective in UK trial

Julie Steenhuysen
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

By Julie Steenhuysen

CHICAGO, Jan 28 (Reuters) - Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.

Novavax said the trial, which enrolled 15,000 people aged 18 to 84, is expected to be used to apply for regulatory review in Britain, the European Union and other countries. Some 27% of people in the trial are over 65.

The study took place as the more easily transmissible UK variant was circulating, and the preliminary analysis suggests the vaccine was 85.6% effective against this mutation, the U.S. company announced in a news release. It did not provide the study data.

(Reporting by Caroline Humer and Julie Steenhuysen; Editing by Bill Berkrot)